Merck (MRK) Announces European Commission Approves KEYTRUDA Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic TNBC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. PRIM
6. META
7. DPZ
8. N2EW34
9. INTC
10. IMNN

Go back to Merck (MRK) Announces European Commission Approves KEYTRUDA Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic TNBC
Merck & Co. (NYSE: MRK) Delayed: 115.48 --0 (-0%)
Previous Close $115.48    52 Week High $65.46 
Open $115.48    52 Week Low $47.97 
Day High $115.48    P/E 78.56 
Day Low $115.48    EPS $1.47 
Volume 22,099